Moving from Vial to Prefilled Syringe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Moving from Vial to Prefilled Syringe
A Project Manager's Perspective.


Pharmaceutical Technology


Scenario one: liquid vial to liquid prefilled syringe

A company markets a contrast imaging agent used in the imaging of major organs. Originally available in 50-mL, 100-mL, and 200-mL single-use vials for intravenous and intra-arterial administration, the company seeks to make the product available in 10-mL and 50-mL prefilled syringes for intrathecal administration for imaging the spinal cord and nervous system. The 50-mL syringe also would be used in the previously approved routes of administration and indication.

In this situation, it is important to consider which factors change and which remain the same. The container–closure system are new, meaning a new size and dimension of container and new functionality of the device are involved. Because the device would enable administration directly into the spinal cord, the route of administration is new, as is the indication. The formulation and long-term storage conditions remain the same, however, because the contrast imaging agent was previously available in a liquid vial.

In selecting a syringe system, the company chooses a device with components similar to those used in the single-use vials. Because the glass and rubber formulation are identical between vial and syringe, previous extractable and leachable studies will apply. However, the company must compare all the materials in the container–closure system because some new materials may be introduced in the components. In addition, the syringe may require additional siliconization to improve the function of the plunger.

To support the regulatory filing, the company will need to submit three months of comparative accelerated stability data. Long-term data on at least one batch, possibly three, will be needed at the time of submission. Moreover, the company will need to commit to placing the first of three production batches on long-term stability and to placing another batch on long-term stability each year. Additional clinical data also will be needed to support the new indication and the new intrathecal route of administration.

Scenario two: lyophilized vial to prefilled syringe

A company producing a lyophilized product packaged with reconstitution fluid for intramuscular injection considers marketing a prefilled syringe for the same indication, in the management of rheumatoid arthritis. The company must reformulate the molecule to a stable liquid. The route of administration will remain the same.

The container–closure device, however, will change, which means that some materials and the functionality of the system will be different. In addition, long-term storage conditions may change because of the new formulation.

When evaluating a syringe system, the company must choose one with components that are similar to those used in the vial and reconstitution device to best leverage previously conducted extractable and leachable studies. As with other prefilled syringes, additional siliconization may be necessary. Clinical studies will be required as well if the degradation or impurity profile changes.

Upon submission, FDA will require three months of comparative accelerated data and long-term data on three batches of drug product. The stability tests will need to focus on appearance, color, clarity, sterility, pyrogens, syringe functionality, container– closure integrity, impurities, and particulates. The company also will need to commit to placing the first three production batches and annual batches on long-term stability tests.

Conclusion

The process of moving an injectable therapeutic from a vial presentation into a prefilled syringe or, perhaps, into an autoinjector format, can be complex, regardless of whether the original product is in a liquid or lyophilized formulation. Companies pursing a new dosage form must carefully document the sterility and purity of the product and ensure the stability of the molecule in the new container–closure system. Complexity of the process multiplies when the dosage form is to be marketed on a global scale. Countries differ in the interpretation of regulatory guidelines established through the International Conference on Harmonization (10).

To ensure a smooth and speedy transition to a new dosage form, most companies assign responsibility for the change- management process to a project manager, who coordinates roles and responsibilities of the team involved in the project, establishes processes and procedures, and manages regulatory submission timelines. Working with team members, the project manager develops and implements the regulatory strategy to control and properly validate the effect of new processes and materials on the therapeutic molecule.

The project manager also helps to select and coordinate the efforts of external partners, including research organizations, suppliers, and manufacturers. The choice of these external partners is critical, particularly for companies with limited experience with multiple regulatory authorities or with the formulation or manufacturing of therapeutic molecules. For example, a contract manufacturing organization with a drug master file on record with FDA for its facilities, processes, or other articles used in the manufacturing, processing, packaging, or storage can help reduce the amount of paperwork that must be submitted. Moreover, in some instances, having a fill–and–finish site that passed inspections within the past year may limit the need for an additional visit by that inspectorate before regulatory approval.

When working with injectable therapeutics, the fastest and most efficient path to market for a new delivery device is one in which processes are rigorous, documentation is thorough, and team members are experienced and capable. The project manager can facilitate a smooth transition to the new dosage form by developing and carefully implementing the regulatory strategy and by choosing qualified, effective partners.

Raul Soikes is senior director of program management at Baxter BioPharma Solutions, 927 South Curry Pike, Bloomington, IN 47403, tel. 812.355.5247,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here